- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 261/16 - Benzènesulfonamido isoxazoles
Détention brevets de la classe C07D 261/16
Brevets de cette classe: 65
Historique des publications depuis 10 ans
|
6
|
8
|
6
|
8
|
3
|
4
|
6
|
0
|
4
|
0
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Xenon Pharmaceuticals Inc. | 194 |
7 |
| Eastern Virginia Medical School | 64 |
3 |
| The Regents of the University of California, Santa Cruz | 17 |
3 |
| Thomas Jefferson University | 556 |
3 |
| Biofront Ltd. (Cayman) | 17 |
3 |
| Dompé Farmaceutici S.p.A. | 301 |
2 |
| Elara Pharmaceuticals GmbH | 9 |
2 |
| European Molecular Biology Laboratory (embl) | 22 |
2 |
| Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | 380 |
2 |
| Sanford-Burnham Medical Research Institute | 123 |
2 |
| Theaprin Pharmaceuticals Inc. | 33 |
2 |
| Shanghai Hansoh Biomedical Co., Ltd. | 364 |
2 |
| Nissan Chemical Corporation | 2273 |
2 |
| The Royal Institution for The Advancement of Learning / McGill University | 718 |
2 |
| The United States of America Department of Health | 2 |
2 |
| Novartis Pharma AG | 277 |
1 |
| Boehringer Ingelheim International GmbH | 4479 |
1 |
| Centre National de La Recherche Scientifique | 11111 |
1 |
| Vertex Pharmaceuticals Incorporated | 1577 |
1 |
| Curegenix, Inc. | 15 |
1 |
| Autres propriétaires | 21 |